Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET: Combination Therapy in Advanced Pancreatic Cancer
NCT00260364Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Nov 2005
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, gemcitabine, bevacizumab, capecitabine in pancreatic cancer (PC), sponsored by Royal Marsden NHS Foundation Trust. Started Nov 2005; status: completed.
02
Drugs
erlotinibgemcitabinebevacizumabcapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00260364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00260364.